219 related articles for article (PubMed ID: 34417112)
1. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
3. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
4. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Iguratimod in Treating Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
Pu J; Wang X; Riaz F; Zhang T; Gao R; Pan S; Wu Z; Liang Y; Zhuang S; Tang J
Front Pharmacol; 2021; 12():621208. PubMed ID: 33815105
[No Abstract] [Full Text] [Related]
6. Is Chinese herbal formula (nourishing Yin therapy) effective and well tolerated as an adjunct medication to hydroxychloroquine in the treatment of primary Sjögren's syndrome? A meta-analysis of randomised controlled trials.
Li S; Ou R; Liu D; Chen Z; Wei S; Li X; Zhang X; Liu Y; Hou C
Ther Adv Chronic Dis; 2022; 13():20406223221077966. PubMed ID: 35251586
[TBL] [Abstract][Full Text] [Related]
7. Combined use of total glucosides of paeony and hydroxychloroquine in primary Sjögren's syndrome: A systematic review.
Zhang A; Chen S; Lin R
Immun Inflamm Dis; 2023 Oct; 11(10):e1044. PubMed ID: 37904705
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Oral Hydroxychloroquine in the Treatment of Ophthalmic Disease Associated with Sjögren's Syndrome.
Fang W; Qingqing Z; Qihui L; Bing Z; Xinyue H; Jie X
Altern Ther Health Med; 2023 Nov; 29(8):656-662. PubMed ID: 37678871
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
12. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
Front Immunol; 2019; 10():1527. PubMed ID: 31354708
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis.
Hu G; Yu YF; Yin S; Yang XY; Xu Q; You H
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7544-7556. PubMed ID: 37667931
[TBL] [Abstract][Full Text] [Related]
15. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
16. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
17. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
18. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.
Wang SQ; Zhang LW; Wei P; Hua H
BMC Musculoskelet Disord; 2017 May; 18(1):186. PubMed ID: 28499370
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the clinical efficacy of yiqi fumai injection combined hydroxychloroquine sulfate tablet for treating Sjogren's syndrome].
Chen FY; Xue B; Wang H
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Dec; 32(12):1621-3. PubMed ID: 23469599
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Traditional Chinese Medicine in Treatment of Primary Sjögren's Syndrome Patients: A Meta-analysis.
Liu H; Wang X; Liu W; He G; Liang X; Bian Y
Comb Chem High Throughput Screen; 2023; 26(14):2554-2571. PubMed ID: 36959129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
